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Abstract 1 
Objective 2 
To evaluate the clinical and cost impact of switching Angiotensin Receptor Blockers (ARBs) 3 
to Angiotensin-Converting Enzyme Inhibitors (ACEIs) in patients with hypertension. 4 
Methods 5 
This study used the UK Clinical Practice Research Datalink, linking with the Hospital Episode 6 
Statistics (April-2006 to March-2012). Adults with hypertension (n=470) were followed from 7 
the first ARBs prescription date to the switching date (pre-switching period); then from the 8 
switching date to the date when study ended, patient left the dataset or died (post-switching 9 
period). Patients were divided into ACEIs-combined (n=369) and ACEIs-monotherapy (n=101) 10 
groups by whether additional antihypertensive drugs were prescribed with ACEIs in the post-11 
switching period. Proportion of Days Covered (PDC), clinical outcomes and costs were 12 
compared between the pre- and post-switching periods using a multilevel regression. 13 
Results 14 
Overall, in the post-switching period, there was a significant increase in the proportion of non-15 
adherence (PDC<80%) (OR: 2.4; 95%CI: 1.6, 3.7), but a significant reduction in mean SBP 16 
(mean difference [MD]: -2.3; 95CI: -3.4, -1.2mmHg) and mean DBP (MD: -1.9; 95%CI: -2.6, 17 
-1.2mmHg). However, these results were only observed in the ACEIs-combined group. There 18 
was no post-switching significant difference in either the incidence of individual or composite 19 
HT-related complications (OR: 0.9; 95%CI: 0.4, 2.0). There was a significant reduction in the 20 
overall annual medical cost per patient by £329 (95%CI: -534, -205). 21 
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Conclusions 22 
 Switching of ARBs to ACEIs monotherapy appeared to be clinically-effective and a cost-23 
saving strategy. The observed changes in the ACEIs-combined group are assumed to be related 24 
to factors other than the ARBs switching.  25 
 26 
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Introduction 33 
Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are 34 
recommended as the first-line treatment of hypertension (HT) by most of the international 35 
guidelines[1, 2]. Their increasing utilisation has accounted for a significant part of total 36 
medicine use across Europe. From 2001-2007, ACEIs/ARBs utilisation significantly increased 37 
across six European countries[3] and contributed to a major part of the total increase of 38 
medicine expenditure[4]. In 2011, they accounted for 6% of all the prescribed medicines in the 39 
UK[5]. Consequently, many countries worldwide have initiated prescribing efficiency 40 
strategies to optimise the use of ACEIs/ARBs[3]. 41 
 42 
In 2009, a Better Care Better Value (BCBV) prescribing indicator for ACEIs/ARBs was 43 
implemented in the UK,[6] which encouraged prescribers to initiate adults with hypertension 44 
on ACEIs and actively switch established ARB users to ACEIs when appropriate. A cost-45 
saving was expected to achieve by switching ARBs to ACEIs due to the differential cost 46 
between ARBs and ACEIs[7]. However, since ACEIs and ARBs have comparable effects in 47 
reducing cardiovascular disease (CVD) mortality and morbidity[8], it was also assumed that 48 
the ‘therapeutic switching’ between these two classes with a different mechanism of actions 49 
and active chemical entities[9] would not compromise the quality of care. However, this 50 
assumption is neither evidence-based nor has it been tested. 51 
 52 
Previous studies demonstrated that policy-induced changes in prescribing patterns may not 53 
always translate into expected changes in patient outcomes[10]. Therefore, rigorous assessment 54 
of effects on patient outcomes is especially crucial given General Practitioners’ (GPs’) 55 
concerns over potential deterioration in patients’ quality of care that some anticipated to result 56 
from the policy-promoted switching of patients from ARBs to ACEIs[11]. Various factors that 57 
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lead to failure in therapeutic switching and consequently jeopardise the clinical effectiveness 58 
of therapy[9] have been suggested in previous literature, including the lack of guidance for 59 
prescribers to implement the switching, and post-switching reduction in patients’ adherence 60 
due to switching to a drug with a lower adherence profile[12], patient’s confusion and concerns 61 
resulting from changes in the drug’s package, taste and/or appearance[13], and patients’ 62 
negative expectations about switching (nocebo effect)[14]. These factors could also apply to 63 
the switching of ARBs to ACEIs. 64 
 65 
Consequently, the overall cost-saving from switching to a cheaper drug may be offset by 66 
spending elsewhere in the health care system, resulting from the implementation or 67 
management of the adverse consequences of the switching[15]. For example, administration 68 
costs, additional visits for dose titration, follow-up and laboratory tests required to implement 69 
the switching, and hospitalisation costs needed to manage the consequence of inadequate blood 70 
pressure (BP) control[15]. Therefore, due to the lack of empirical evidence to support the 71 
therapeutic switching of ARBs to ACEIs, this study aimed to investigate the unanticipated 72 
impact of switching ARBs to ACEIs in adults with hypertension on adherence to ARBs and 73 
ACEIs, clinical effectiveness and overall changes in the National Health Service (NHS) costs.  74 
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Methods 75 
Study design and data source 76 
This retrospective cohort study used the UK primary care dataset – the Clinical Practice 77 
Research Datalink (CPRD)[16] in linkage with the hospitalisation dataset in England – the 78 
Hospital Episode Statistics (HES)[17] from April-2006 to March-2012. CPRD contains 79 
longitudinal electronic records (including patient demographics, medical diagnosis, and 80 
prescribed medications) for about 8.5% of the UK population. It has been considered broadly 81 
representative regarding practice and patient characteristics in the UK[18]. In addition, 65% of 82 
the English practices in the CPRD consent to data linkage with the HES[19]. The study protocol 83 
was approved by the Independent Scientific Advisory Committee of CPRD (protocol number 84 
13-150). 85 
 86 
Study cohort 87 
Adults (≥18 years old) with primary hypertension, without a previous CVD and chronic kidney 88 
disease (CKD), and registered in the HES-consenting practices were identified by relevant 89 
Read codes (standard clinical terminology system used in the CPRD). Eligible patients who 90 
were issued with ARB during the study period were followed from their first ARB prescription 91 
date (index date) to the date when they switched to ACEIs (pre-switching period), and then 92 
from the switching date to the date when study ended, patient left the dataset or died (post-93 
switching period) whichever happened first. According to previous literature, switching was 94 
defined as discontinuation of ARBs therapy and starting of ACEIs within a ‘switching window’ 95 
to equal the duration of one prescription supply [20], which was 30 days on average in this 96 
study. 97 
 98 
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During the pre-switching period, the study cohort was prescribed with only ARBs as 99 
antihypertensive treatment. Considering the effect of combining additional antihypertensive 100 
medications with ACEIs in the post-switching period, the study cohort was sub-grouped by 101 
whether other antihypertensive medicines were prescribed to ACEIs in the post-switching 102 
period into the ACEIs-combined and ACEIs-monotherapy group, respectively. 103 
 104 
All the seven ARBs (losartan, candesartan, valsartan, telmisartan, irbesartan, olmesartan, 105 
eprosartan) and the 11 ACEIs (ramipril, enalapril, lisinopril, captopril, cilazapril, quinapril, 106 
fosinopril, imidapril, moexipril, trandolapril, Perindopril) that were available in the UK during 107 
the study period were included in this study. As this study aimed to evaluate the impact of 108 
switching between the ARB and ACEI classes rather than individual ARBs and ACEIs, the 109 
types and daily dosages of the individual ARBs and ACEIs were not specified in the analysis. 110 
Given the relatively uncomplicated dosing schedules for ARBs and ACEIs in treating 111 
hypertension and evidence that GPs in the UK generally follow the recommendations in British 112 
National Formulary (BNF)[21, 22] , we assumed that ARBs/ACEIs were prescribed according 113 
to their recommended doses in the BNF. 114 
 115 
Outcome measures 116 
Adherence to antihypertensive medications, BP, HT-related complications and healthcare 117 
resource utilisation and costs (Table 1) were measured in both the ‘pre-switching’ and ‘post-118 
switching’ period of the two study subgroups. 119 
 120 
The proxy for adherence - the proportion of Days Covered (PDC) for ARBs and ACEIs were 121 
measured in the pre- and post-switching period, respectively, by dividing the total number of 122 
days covered by the drug prescription by the number of days in the follow-up time in each 123 
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period, and was truncated at 100% [23]. A standard cut-off point of 80% was applied to 124 
categorise the patient as adherent (PDC≥80%) and non-adherent (PDC<80%)[24], then the 125 
proportion of non-adherent patients was estimated. 126 
In each period, mean systolic (SBP) and diastolic (DBP) BP were calculated as the average of 127 
the last three measurements. Furthermore, the incidence of individual and composite HT-128 
related complications, including stroke, myocardial infarction (MI), angina, heart failure, and 129 
chronic kidney diseases were identified by applying previously validated ICD-10 diagnosis 130 
codes[25] to hospitalisation episodes in HES. HT-related healthcare resource utilisation was 131 
collected from primary and secondary care settings (Table 1). Individuals’ resource utilisation 132 
was multiplied by the assigned unit cost to obtain the overall direct annual medical cost for 133 
each patient in each period. 134 
 135 
Covariates 136 
Patients’ baseline characteristics including demographics (age, gender), and clinical 137 
characteristics, e.g. SBP, DBP, smoking status, body mass index, serum cholesterol and 138 
comorbidity measured using the Charlson comorbidity index (CCI)[26] were obtained at the 139 
index date. Prevalent HT patients and prevalent ARBs uses were defined as having any HT 140 
diagnosis codes or prescribed ARBs in the year before the index date; otherwise classified as 141 
incident HT patients and user, respectively. 142 
 143 
Data analysis 144 
Baseline characteristics were reported by descriptive statistics (mean and standard deviation 145 
for continuous variables; frequency and proportions for categorical variables) and the 146 
differences between subgroups were tested by the unpaired t-test and Chi-square test. 147 
Univariate analyses were undertaken in a self-controlled pre- and post- comparison framework 148 
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by applying appropriate statistical tests suitable for the outcome variables (Table 1). 149 
Furthermore, multilevel, mixed-effects regression modelling[27] was used to compare 150 
adherence, BP and HT-related complications pre- and post-switching, while adjusting for 151 
covariates. The results were presented as adjusted odds ratio (aOR) or adjusted mean difference 152 
(aMD) with their 95% confidence interval (CI). Patient’s baseline characteristics (Table 2) 153 
such as age, gender, and smoking were not included in the adjustment models as individuals 154 
acting as a control for themselves.  155 
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Results 156 
Baseline characteristics 157 
About 5% (n=2,304) of patients (n=46,193) who switched their antihypertensive medications 158 
were ARBs switchers; of which 45.7% (n=1,053) switched from ARBs to ACEIs during the 159 
study period; of which, only 44.6% (n=470) patients were identified in the practices linked 160 
with HES, and hence were eligible for inclusion in this study. Patients in the ACEIs-combined 161 
(n=369; 78.5%) and ACEIs-monotherapy groups (n=101; 21.5%) had similar characteristics 162 
(Table 2), except for significantly more non-smokers in the ACEIs-combined group (58.0% 163 
vs. 47.5%, p<0.05). 164 
 165 
Proportion of days covered and proportion of non-adherent patients 166 
Comparing the post-switching against pre-switching period, the significant difference in 167 
adherence to antihypertensive medicating was only observed in the ACEIs-combined group. 168 
For example, the median PDC was significantly lower (99.2% vs. 97.9%, p<0.001) (Table 3); 169 
similarly, the proportion of non-adherent patients (PDC<80%) was significantly higher (17.3% 170 
vs. 29.0%, p<0.001), and consistently, a significantly higher post-switching likelihood of being 171 
non-adherent (aOR: 2.6; 95%CI: 1.6, 4.1) was found in the multivariate regression (Table 3). 172 
 173 
Blood pressure 174 
Likewise, a significant reduction in the mean SBP and DBP in the post-switching period were 175 
only observed in the ACEIs-combined group (Table 3); consistently, a significant post-176 
switching reduction in both mean SBP (aMD [mmHg]: -2.2; 95%CI: 3.5, -1.0) and DBP (aMD: 177 
-2.1; 95%CI: -2.9, -1.4) after adjusting for covariates was only observed in the ACEIs-178 
combined group (Table 3). 179 
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Incidence of hypertension-related complications 180 
Of the 70 HT-related events identified from 40 patients; there was no significant difference in 181 
the incidence of individual or composite HT-related complications comparing post-switching 182 
against the pre-switching period, except for a significantly lower incidence of MI in the post-183 
switching period (13% vs. 3%, p<0.001), which was only observed in the ACEIs-combined 184 
group. Consistently, the multivariate regression indicated no significant difference in risk of 185 
individual and composite HT-related complications, except for a significantly lower risk of MI 186 
(aOR: 0.1; 95%CI: 0.04, 0.6) the post-switching period (Table 4). 187 
 188 
Healthcare resource utilisation and costs  189 
There was higher healthcare resource use identified in the post-switching period, except for a 190 
lower and non-significant number of hospitalisations (Table 5). Overall, the median number of 191 
GP consultations was higher in the post-switching period compared with the pre-switching 192 
period, but this was statistically non-significant (4.1 vs. 3.6, p>0.05). The total direct cost of 193 
healthcare resource utilisation was significantly lower in the post-switching period (Figure 1). 194 
The bootstrapping analysis indicated a significantly lower total mean annual cost per patient in 195 
the post-switching period (£630 vs. £300.9; MD: -£329.2; 95%CI: -534.6, -205.7), regardless 196 
of stratifying the analysis by ACEIs-combined (MD: -£393.2; 95%CI: -665.3, -242) or ACEIs-197 
monotherapy group (MD: -£95.1; 95%CI: -132.1, -39.0) (Table 6). This overall cost reduction 198 
was driven mainly by the significant decrease in the cost of antihypertensive drugs in the post-199 
switching period. The costs of GP consultations and outpatient clinic attendance were not 200 
significantly different between the pre- and post-switching period. 201 
 202 
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Discussion 203 
This study investigated a crucial prescribing issue which affects a large number of adult 204 
patients under the care of GPs by assessing the clinical and economic impact of the ARBs 205 
switching promoted by the BCBV policy. This study found that switching ARBs to ACEIs in 206 
adults with primary hypertension in current practice had no negative impact on medication 207 
adherence, clinical outcomes, and resulted in an overall direct medical cost saving. The results 208 
suggested there was no concern over compromising patients’ quality of care caused by ARBs 209 
switching to ACEIs[11].  210 
 211 
The small number of ‘switchers’ identified in this study indicates that switching hypertensive 212 
patients from ARBs to ACEIs appears to be uncommon in the UK. This could be attributed to 213 
the lack of an effective, national switching policy to promote switching ARB to ACEIs actively. 214 
Our previous study has shown that the BCBV indicator was ineffective[28] due to several 215 
implementation barriers[29]. Furthermore, the superior tolerability profile[30] and strong 216 
pharmaceutical marketing of ARBs[31] could also contribute to the low ARBs switching rate. 217 
 218 
Although the previous literature has found that switching of antihypertensive drugs was 219 
associated with lower medication adherence; in this study, a significant reduction in post-220 
switching adherence was only observed in the ACEIs-combined group, which suggests that the 221 
reduced adherence was primarily associated with the additional antihypertensive drugs 222 
prescribed, i.e. the complexity of therapeutic regime rather than the switching. The negative 223 
association between adherence and increasing the complexity of a therapeutic regimen[32] as 224 
a result of increasing the number of prescribed antihypertensive drugs[33] has been well-225 
documented in the literature.  226 
 227 
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In addition, the comparable adherence profile between ACEIs and ARB[12, 31, 34] and the 228 
increasing patient involvement in their healthcare decision that in UK healthcare settings[35, 229 
36] could attribute to the lack of association between switching and adherence to ARB found 230 
in this study. The increase of patient involvement has been observed in several UK studies[37, 231 
38] that evaluated medication switching, including the switching of antihypertensive drugs, 232 
and involving patients in their treatments is believed to improve patients’ engagement and 233 
adherence to treatment regimen. 234 
 235 
Similar to the effect of ARBs switching on adherence, the significant reduction of both SBP 236 
and DBP was only observed in the ACEIs-combined group after switching. Since ARBs and 237 
ACEIs have similar efficacy in lowering BP[39], this result also indicates that the reduction of 238 
BP may be related to factors other than the switching, such as the additional or synergic effects 239 
of combining other antihypertensive drugs with ACEIs leading to a higher BP reduction[40].  240 
 241 
At first glance, the observed significant reduction in BP (better BP control) in the ACEIs-242 
combined group despite a significant decrease in medicine adherence (poor adherence) after 243 
switching seems to contradict the notion that poor adherence leads to suboptimal BP control[2]. 244 
However, a statistically significant reduction in adherence may not always result in clinically 245 
relevant BP control[41]. 246 
 247 
It was not surprising to find that ARBs switching did not significantly impact on patients' HT-248 
related complications in the ACEI-monotherapy group due to the small sample and tiny 249 
changes in adherence and BP in the post-switching period. In contrast, the significant reduction 250 
of the MI risk in the ACEIs-combination group could result from the significant reduction in 251 
BP after switching[42]. 252 
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Although it has been reported that cost-savings from medication switching could be potentially 253 
offset by spending elsewhere in the healthcare system[9, 15], switching of ARBs to ACEIs in 254 
this study was not associated with any additional costs to offset the cost-saving resulted from 255 
ARBs switching to ACEIs. Recently, several generic ARBs were launched which might 256 
moderate the observed switching-related cost-saving in this study. However, currently, generic 257 
ACEIs are still cheaper than generic ARBs[43]; according to the UK national list prices[43], 258 
the cost of 28-day treatment supply of generic candesartan, irbesartan, and valsartan is 16%, 259 
41% and 148% higher than generic ramipril, respectively.  260 
 261 
Furthermore, although there was no significant difference in the median of numbers of GP 262 
consultations between the pre- and post-switching period, the total number of GP consultations 263 
was higher in the post-switching period, but the total cost was lower. This difference in cost 264 
could be related to the different type and/or length of consultations (face to face vs. telephone 265 
consultations) between the pre- and post-switching period; for instance, there was a greater 266 
proportion of telephone consultations and shorter face to face consultations (mean duration: 267 
11.2 vs. 12.4 minutes) in the post-switching period compared with the pre-switching period. 268 
 269 
Watman (2013) evaluated the impact of switching ARBs to ACEIs in 435 patients with primary 270 
hypertension[37] and reported similar findings to this study regarding insignificant changes in 271 
BP, hospitalisation, and overall cost-saving. However, Watman (2013) only followed up 272 
patients for 12 months and considered only drug acquisition costs and staff costs involved in 273 
implementing the switching[37]. Therefore, it did not demonstrate the complete picture of the 274 
full clinical and economic implications of switching ARBs to ACEIs.  275 
 276 
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This is the only population-based study that has assessed the full clinical and economic 277 
consequences of switching from ARBs to ACEIs, considering both short-term surrogate 278 
markers (adherence and BP), longer-term clinical outcomes (HT-related complications) and 279 
healthcare costs. The self-control design has been suggested to have higher statistical power 280 
compared with the parallel two-sample design (intervention vs control)[44], and this study had 281 
sufficient power to detect the significant difference in the outcomes of SBP, DBP and overall 282 
cost. It was not possible to identify the reasons for ARBs switching. Switching could occur for 283 
clinical (intolerance, treatment failure and development of other comorbid conditions[20]) or 284 
cost-saving reasons, all rarely or inconsistently recorded in the databases. Switching due to 285 
intolerance to ARBs is considered relatively unlikely given their better[13, 45] or at least 286 
similar[12, 31] tolerability profile compared with ACEIs. Switching due to treatment 287 
failure/clinical ineffectiveness is also regarded as unlikely as ARBs and ACEIs have 288 
comparable clinical efficacy[8, 39]. ACEIs have similar or broader license indications than 289 
ARBs,[46] so it is doubtful that GPs would switch patients from ARBs to ACEIs in response 290 
to the development of new comorbid conditions.   291 
 292 
Therefore, after ruling out these clinical reasons, cost-saving is assumed to underpin most of 293 
these switching activities. This study was limited in size by only including patients from HES-294 
consenting practices. Nevertheless, patients from HES-consenting practices have shown to be 295 
representative of the whole CPRD registrants regarding demographics, major prescriptions and 296 
hospitalisations[19]. The number of patients included in this study was higher than the amounts 297 
reported in previous clinical trials or observational studies[37, 38, 47], which evaluated the 298 
clinical and economic impact of antihypertensive drug switching other than ARBs to ACEIs.  299 
 300 
17 
 
Arguably, the study findings might be limited by the small number of CV events and the 301 
relatively medium follow-up period; however, it is unlikely that a longer follow-up time would 302 
have affected the results since there was no increase in BP, which is the typical, most reliable 303 
and well-evaluated surrogate marker for CVD[48]. As this study used healthcare databases, it 304 
was not possible to include the cost of implementing ARBs switching. The cost of staff 305 
involved in implementing the switching would not persist over time, whereas the overall cost-306 
saving of ARBs switching is a continuous cost-saving generated from the chronic, lifetime use 307 
of cheaper ACEIs once switched from more expensive ARBs[37]. 308 
 309 
It is possible that this study results might be extrapolated to other drug classes or molecules, 310 
including other antihypertensive drug classes, which, similar to ARBs and ACEIs, have 311 
comparable clinical efficacy, safety profile, and dosing schedule. However, due to the complex 312 
and multifactorial nature of the switching process and disease conditions, the extrapolation of 313 
this research findings needs further investigation. 314 
 315 
Conclusions 316 
Switching adults with hypertension from ARBs to ACEIs appeared to do not compromise 317 
patients’ adherence and clinical outcomes but resulted in overall cost-savings. Therefore, on 318 
this occasion and in this setting, it could be concluded that switching of ARBs to ACEIs can 319 
be considered a safe and clinical-effective cost-containment strategy, which could be used as 320 
evidence by clinicians and policymakers to make informed, more confident decisions about 321 
therapeutic switching of ARBs to ACEIs. 322 
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Figure legends  
Figure 1. Mean total annual cost of healthcare resource use per patient, comparing 
post- and pre-switching periods 
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Tables  
Table 1. Summary of the study outcomes with their associated data sources and univariate analyses 
Outcome category Outcome measures Data source Outcome Univariate analysis 
Adherence to 
antihypertensive 
medications 
Proportion of Days Covered (PDC) by ARBs or 
ACEIs prescription 
CPRD-Therapy file Median and interquartile range 
(IQR) of PDC 
Wilcoxon signed-rank sum 
test 
Proportion of non-adherence 
patients (PDC<80%) 
McNemar's test 
Blood pressure (BP) Systolic blood pressure and diastolic blood 
pressure 
CPRD-Medical file Mean systolic and diastolic BP Paired t-test 
Hypertension (HT)-
related complications 
A composite of any event of a stroke, myocardial 
infarction, angina, heart failure, and chronic 
kidney diseases 
HES-Inpatient dataset Proportion of patients 
experienced any HT-related 
complications 
McNemar's test 
Healthcare resource 
utilisation 
Number of HT-related GP visits and consultations CPRD-Medical file 
Median (IQR) of the outcome 
measures  
Wilcoxon signed-rank sum 
test 
Number of prescriptions of antihypertensive 
medicines 
CPRD-Therapy file  
Number of HT-related hospital admissions HES-Inpatient dataset 
Number of HT-related outpatient attendance CPRD-Referral file  
Cost Cost/minute for HT-related GP consultations PSSRU[49] Annual costs from the 
bootstrapping approach 
Paired t-test on the data 
generated from the 
bootstrapping approach[50]  
Cost of individual antihypertensive medication  BNF[51] 
Cost/HT-related hospitalisation episode and 
attendance at outpatient clinics 
NHS reference cost[52] 
(Note) CPRD: Clinical Practice Research Datalink; HES: Hospital Episode Statistics; PSSRU: Personal Social Services Research Unit; BNF: British National Formulary 
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Table 2. Baseline characteristics of the study cohort and subgroups 
 
Total 
(n=470) 
ACEIs-combined 
group (n=369) 
ACEIs-
monotherapy 
group (n=101) 
Mean age (±SD) 59.1±12.5 59.4±12.8 57.9±11.5 
Gender    
Male  281 (59.8%) 225 (61.0%) 56 (55.5%) 
Female  189 (40.2%) 144 (39.0%) 45 (44.5%) 
Mean BP (mmHg)    
Mean SBP (±SD)  147.2±18.4 147.3±18.6 146.8±17.8 
Mean DBP (±SD) 86.6±11.5 86.6±11.5 86.6±11.8 
Mean BMI (±SD)  28.6±5.4 28.8±5.2 28.0±6.1 
Mean serum cholesterol (mmol/L) 
(±SD) 
5.1±1.1 5.1±1.2 5.2±1.0 
Charlson comorbidity index    
0 286 (60.9%) 218 (59.1%) 68 (67.3%) 
1 112 (23.8%) 92 (24.9%) 20 (19.0%) 
≥2 72 (15.3%) 59 (16.0%) 13 (12.9%) 
Smoking status    
Non- smokers 262 (55.7%) 214 (58.0%)* 48 (47.5%)* 
Smokers 75 (16.0%) 52 (14.1%) 23 (22.8%) 
Ex-smokers 133 (28.3%) 103 (27.9%) 30 (29.7%) 
Drug use status    
Incident 146 (31.1%) 117 (31.7%) 29 (28.7%) 
Prevalent 324 (68.9%) 252 (68.3%) 72 (71.3%) 
Hypertension status    
Incident 116 (24.7%) 89 (24.1%) 27 (26.7%) 
Prevalent 354 (75.3%) 280 (75.9%) 74 (73.3%) 
Mean follow-up time (years±SD)   
Pre-switching  2.5±1.7 2.3±1.7 3.1±1.6 
Post-switching  2.6±1.7 2.8±1.7 1.9±1.4 
(Note) * p<0.05 Chi-square test; SD: standard deviation; BP: Blood pressure; BMI: Body mass index 
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Table 3. Proportion of Days Covered and blood pressure comparing post- and pre-switching periods 
 Total (n=470)  
ACEIs-combined group 
(n=369) 
 ACEIs-monotherapy group (n=101) 
 Pre-switching Post-switching  Pre-switching Post-switching  Pre-switching Post-switching 
Proportion of days covered (PDC)         
Median PDC (IQR) 
98.5% 
(89.5-100%) (a) 
97.9% 
(74.7-100%) (a) 
 
99.2% 
(89.5-100%) (a) 
97.9% 
(70-100%) (a) 
 
95.7% 
(90.5-100%) 
98.0% 
(86.0-100%) 
Proportion of patients with PDC<80% 17.0% (b) 27.0% (b)  17.3% (b) 29.0% (b)  15.8% 19.8% 
aOR (95%CI) (c) 2.4 (1.6, 3.7)  2.6 (1.6, 4.1)  1.9 (0.6, 5.6) 
Blood pressure (mmHg)         
Mean SBP (±SD) 143.2±13.1 (d) 141.3±12.8 (d)  144.2±13.4 (d) 141.9±12.5 (d)  139.8±11.4 138.8±13.8 
Mean DBP (±SD) 84.1±8.8 (d) 82.5±8.6 (d)  84.6±8.7 (d) 82.6±8.3 (d)  82.4±8.7 81.9±9.5 
aMD (90%CI) of SBP -2.3 (-3.4, -1.2) (e)  -2.2 (-3.5, -1.0) (e)  -2.0 (-4.8, 0.4) 
aMD (90%CI) of DBP -1.9 (-2.6, -1.2) (e)  -2.1 (-2.9, -1.4) (e)  -1.0 (-2.7, 0.7) 
(Note) SBP: systolic blood pressure; DBP: diastolic blood pressure; IQR: interquartile range; SD: standard deviation; (a) p<0.001 (Wilcoxon signed-rank test); (b) 
p<0.001(McNemar test); (c) aOR: adjusted OR for the proportion of non-adherent patients (PDC<80%), model was adjusted for patients’ follow-up time; aMD: adjusted mean 
difference; (d) p<0.001 (paired t-test); (e) p<0.005 (regression models adjusted for follow-up time and PDC) 
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Table 4. Incidence of hypertension-related complications comparing post- and pre-switching periods 
Number of events 
(%) 
Total 
(n=470) 
aOR (95%CI)# 
ACEIs-combined group 
(n=369) 
aOR (95%CI)# 
ACEIs-monotherapy 
group (n=101) 
aOR (95%CI)# 
Pre-
switching 
Post-
switching 
Pre-
switching 
Post-
switching 
Pre-
switching 
Post-
switching 
Composite 19 (4.0%) 21 (4.5%) 0.9 (0.4, 2.0) 18 (4.9%) 18 (4.9%) 0.7 (0.3,1.6) 1 (1.0%) 3 (3.0%) 4.4 (0.4, 50.2) 
Stroke 1 (0.2%) 2 (0.4%) 1.2 (0.08, 17.8) 0 (0.0%) 1 (0.3%) NA 1 (1.0%) 1 (1.0%) 1.0 (0.08, 14.1) 
MI 13 (2.8%)* 3 (0.6%)* 0.1 (0.04, 0.6) 13 (3.5%)* 3 (1.8%)* 0.1 (0.04, 0.6) 0 (0.0%) 0 (0.0%) NA 
HF 0 (0.0%) 1 (0.2%) NA 0 (0.0%) 1 (0.3%) NA 0 (0.0%) 0 (0.0%) NA 
CKD 0 (0.0%) 1 (0.2%) NA 0 (0.0%) 1 (0.3%) NA 0 (0.0%) 0 (0.0%) NA 
Angina 6 (1.3%) 7 (1.5%) 0.9 (0.2, 3.9) 6 (1.6%) 6 (1.6%) 0.7 (0.1, 3.3) 0 (0.0%) 1 (1.0%) NA 
Atherosclerosis 
and other IHD  
4 (0.9%) 11 (2.3%) 2.1 (0.6, 7.3) 4 (1.1%) 10 (2.7%) 1.7 (0.5, 6.2) 0 (0.0%) 1 (1.0%) NA 
(Note): * p<0.001 (McNemar test); #aOR: adjusted odds ratio, models were adjusted for patients` follow up time, PDC, systolic and diastolic BP, whether the patient 
developed the studied outcome of interest in the pre-switching period; MI: myocardial infarction; HF: heart failure; CKD: chronic kidney disease; IHD: ischaemic heart 
diseases; NA: non-applicable as study subgroups did not develop the complications before or after the switching. 
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Table 5. Total healthcare resource utilisation and associated costs in the pre- and post-switching periods 
Healthcare resources category 
Total (n=470) 
 ACEIs-combined group 
(n=369) 
 
ACEIs-monotherapy group (n=101) 
Pre-switching Post-switching  Pre-switching Post-switching  Pre-switching Post-switching 
GPs consultation 
Quantity  4,359 5,734  3,277 5,075  1,082 659 
Cost 126,361 103,493  111,716 86,770  14,644 16,714 
Antihypertensive drug 
prescription 
Quantity  9,347 14,120  6,909 12,508  2,438 1,612 
Cost 95,543 12,216  79,979 10,603  15,563 1,614 
Hospitalisation 
Quantity  46 33  45 28  1 5 
Cost 73,147 23,800  73,931 21,237  216 2,563 
Outpatient attendance 
Quantity  17 44  12 42  5 2 
Cost 1060 1,891  878 1,786  182 105 
Total 
Quantity  13,769 19,931  10,243 17,653  3,526 2,278 
Cost 296,111 141,400  266,504 120,396  30,605 20,996 
(Note) ACEIs: Angiotensin-Converting Enzyme Inhibitors 
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Table 6. Mean total annual cost (in British Pounds) of healthcare resource utilisation per patient in the post-switching period compared with 
the pre-switching period 
 
Total (n=470)  ACEIs-combined group (n=369)  ACEIs-monotherapy group (n=101) 
Pre-switching Post-switching  Pre-switching Post-switching  Pre-switching Post-switching 
GPs consultations        
Mean cost (a) 268  (212.2 to 457.4) 220.2 (202.4 to 248)  302.8 (227.5 to 520) 235 (212.5 to 264)  145 (125 to 172.8) 165.5 (136 to 210) 
Cost difference (a) -48.7 (-227.4 to 10.0), P=0.382 (b)  -67.6 (-283.8 to 14.4), P=0.348 (b)  20.5 (-14.7 to 64.5), 0.315 (b) 
Antihypertensive drugs prescriptions         
Mean cost (a) 203.3 (173.8 to 272) 26.0 (27.0 to 28.5)  216.7 (181.8 to 317) 28.7 (26.1 to 31.8)  154.1 (146 to 162) 16.0 (14.6 to 18.1) 
Cost difference (a) -177.3 (-246.6 to-148.0), P=0.025 (b)  -188.0 (-288.0 to-153.4), P=0.021  -138.1 (-146.3 to-131.1), P<0.001 (b) 
Hospitalisations         
Mean cost (a) 155.6 (86.9 to 304.2) 50.6 (27.3 to 93.4)  197.6 (106.3 to 367) 57.6 (27.1 to 108.2)  2.2 (0.0 to 12.9) 25.4 (7.7 to 82.3) 
Cost difference (a) -105.0 (-251.0 to -31.1), P=0.028 (b)  -140.1 (-308.2 to -49.0), P=0.021 (b)  23.2 (-6.0 to 52.5), P=0.117 (b) 
Outpatients attendance        
Mean cost (a) 2.3 (1.2, 4.3) 4.0 (2.6, 6.7)  2.4 (1.1, 4.9) 4.8 (2.9, 8.6)  1.8 (0.4, 4.8) 1.0 (0.3, 4.3) 
Cost difference  (a) 1.8 (-0.5, 4.2), P=0.138 (b)  2.4 (-0.2, 5.4), P=0.10 (b)  0.8 (-3.6, 1.6), P=0.585 (b) 
Total cost         
Mean cost  (a) 630.0 (506.7 to 844) 300.9 (269.3 to 350)  719.5 (565.8 to 979) 326.3 (288 to 387)  303 (281.6 to 329) 207.9 (172 to 274) 
Cost difference  (a) -329.2 (-534.6 to -205.7); P=0.011 (b)  -393.2 (-665.3 to -242), P=0.01 (b)  -95.1 (-132.1 to -39.0); P=0.002 (b) 
(Note) (a) Bootstrapped bias-corrected and accelerated 95% confidence interval (95%CI); (b) Bootstrapped paired t-test p-value 
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Figure 1 
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